id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-312027-5tntdjp9	Charlton, Carmen L.	Evaluation of Six Commercial Mid- to High-Volume Antibody and Six Point-of-Care Lateral Flow Assays for Detection of SARS-CoV-2 Antibodies	2020-09-22		.txt	text/plain	4210	202	47	We performed a head-to-head assessment of enzyme immunoassays (EIAs) and point-of-care lateral flow assays (POCTs) to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. Six EIAs (Abbott, Affinity, Bio-Rad, DiaSorin, Euroimmun, and Roche) and six POCTs (BTNX, Biolidics, Deep Blue, Genrui, Getein BioTech, and Innovita) were evaluated for the detection of SARS-CoV-2 antibodies in known COVID-19-infected individuals. To develop a panel of positive sera from patients with COVID-19, serum samples were collected from hospitalized patients confirmed to be positive for SARS-CoV-2 upon nasopharyngeal swab or endotracheal aspirate testing by rRT-PCR. Performance characteristics of EIAs. In total, 46 samples from 28 different patients testing positive for SARS-CoV-2 by rRT-PCR and 50 negative samples from serum samples stored prior to 1 November 2019 were run on each assay. Interestingly, despite four different samples collected from patient 6 (ranging from 18 to 29 days after symptom onset), antibodies were never detected by the Roche assay.	./cache/cord-312027-5tntdjp9.txt	./txt/cord-312027-5tntdjp9.txt